Ebner, Nicole

[["dc.bibliographiccitation.firstpage","3"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","10"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Suzuki, Tsuyoshi"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Palus, Sandra"],["dc.contributor.author","Haehling, Stephan von"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2019-07-08T12:29:23Z"],["dc.date.accessioned","2021-10-27T13:21:17Z"],["dc.date.available","2019-07-08T12:29:23Z"],["dc.date.available","2021-10-27T13:21:17Z"],["dc.date.issued","2019"],["dc.description.abstract","Background: Medroxyprogesterone (MPA) and megestrol acetate (MA) are synthetic progesterone derivates. Progestagen is an approved drug for cancer cachexia in the USA and some Europe. These agents have been described to increase appetite and to lead to weight gain. However, the effects on survival are still unknown. The aim of this study was to evaluate the effects of progesterone on survival, cardiac function as well as appetite and body weight in the Yoshida hepatoma AH‐130 rat cancer cachexia model. Methods: In this study the effects of progesterone were tested in cachectic tumor bearing rats. Rats were treated with 0.5, 5 or 50mg/kg/d, respectively or placebo daily, starting one day after tumor inoculation for a period of 16 days. Cardiac function was analyzed by echocardiography at baseline and at day 11. Food intake was assessed before tumor inoculation and at day 11. Body weight and body composition were evaluated at the beginning and the end of study or day of euthanasia. Results: Survival was significantly improved by 5 mg/kg/d (HR: 0.48, 95%CI: 0.24‐0.95, p=0.0356). However, there was no significant difference between the progesterone treatment groups compared to placebo in body weight change and body composition, as well as food intake on day 11. Cardiac function also showed no significant difference compared to placebo. Conclusion: Progesterone improves survival, but has no beneficial effects on cardiac function, body weight and food intake in this aggressive hepatoma cancer cachexia rat model. Further studies are needed to elucidate the mechanism of the survival benefit."],["dc.description.sponsorship","Open Access-Publikationsfonds 2019"],["dc.identifier.doi","10.1002/rco2.11"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16258"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92008"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Progesterone improves survival in hepatoma cachexia rat model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","90"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","94"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","von Haehling, Stephan"],["dc.date.accessioned","2018-11-07T10:17:21Z"],["dc.date.available","2018-11-07T10:17:21Z"],["dc.date.issued","2016"],["dc.description.abstract","This article highlights pre-clinical and clinical studies into the field of wasting disorders that were presented at the 8th Cachexia Conference held in Paris, France December 2015. This year some interesting results of clinical trials and different new therapeutic targets were shown. This article presents the biological and clinical significance of different markers and new drugs for the treatment of skeletal muscle wasting. Effective treatments of cachexia and wasting disorders are urgently needed in order to improve the patients' quality of life and their survival."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2016"],["dc.identifier.doi","10.1002/jcsm.12106"],["dc.identifier.isi","000373200500010"],["dc.identifier.pmid","27128291"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13409"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41211"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","303"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","311"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Drescher, Cathleen"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T09:48:30Z"],["dc.date.available","2018-11-07T09:48:30Z"],["dc.date.issued","2015"],["dc.description.abstract","Loss of muscle mass arises from an imbalance of protein synthesis and protein degradation. Potential triggers of muscle wasting and function are immobilization, loss of appetite, dystrophies, and chronic diseases as well as aging. All these conditions lead to increased morbidity and mortality in patients, which makes it a timely matter to find new biomarkers to get a fast clinical diagnosis and to develop new therapies. This mini-review covers current developments in the field of biomarkers and drugs on cachexia and sarcopenia. Here, we reported about promising markers, e.g. tartate-resistant acid phosphatase 5a, and novel substances like epigallocatechin-3-gallate. In summary, the progress to combat muscle wasting is in full swing, and perhaps diagnosis of muscle atrophy and of course patient treatments could be soon support by improved and more helpful strategies."],["dc.identifier.doi","10.1002/jcsm.12082"],["dc.identifier.isi","000365536800006"],["dc.identifier.pmid","26676067"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13569"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35319"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","L24"],["dc.bibliographiccitation.issue","Supplement_L"],["dc.bibliographiccitation.journal","European Heart Journal Supplements"],["dc.bibliographiccitation.lastpage","L27"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Lena, Alessia"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Anker, Markus S"],["dc.date.accessioned","2020-12-10T18:19:08Z"],["dc.date.available","2020-12-10T18:19:08Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1093/eurheartj/suz241"],["dc.identifier.eissn","1554-2815"],["dc.identifier.issn","1520-765X"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17208"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75136"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Cardiac cachexia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","218"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","225"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Haehling, Stephan von"],["dc.date.accessioned","2019-08-05T06:53:12Z"],["dc.date.available","2019-08-05T06:53:12Z"],["dc.date.issued","2019"],["dc.description.abstract","This article highlights the updates from preclinical and clinical studies into the field of wasting disorders that were presented at the 11th Cachexia Conference held in Maastricht, the Netherlands, in December 2018. Herein, we summarize the biological and clinical significance of different markers and new diagnostic tools and cut-offs for the detection of skeletal muscle wasting, including micro-RNAs, siRNAs, epigenetic targets, the ubiquitin-proteasome system, mammalian target of rapamycin signalling, news in body composition analysis including the D3-creatine dilution method, and electrocardiography that was modified to enable segmental impedance spectroscopy. Of particular interest were the beneficial effects of BIO101 on muscle cell differentiation, hypertrophy of myofibers associated with mammalian target of rapamycin pathways activation, and the effect of metal ion transporter ZIP14 loss that reduces cancer-induced cachexia. The potential of anti-ZIP14 antibodies and zinc chelation as anti-cachexia therapy should be tested in patients with cancer cachexia. Big randomized studies were presented such as RePOWER (observational study of patients with primary mitochondrial myopathy), STRAMBO (influence of physical performance assessed as score and clinical testing), MMPOWER (treatment of elamipretide in subjects with primary mitochondrial myopathy), FORCE (examined differences in relative dose intensity and moderate and severe chemotherapy-associated toxicities between a strength training intervention and a control group), and SPRINTT (effectiveness of exercise training in healthy aging). Effective treatments were urothelin A, rapamycin analogue treatment, epigenetic factor BRD 4 and epigenetic protein BET, and the gut pathobiont Klebsiella oxytoca. Clinical studies that investigated novel approaches, including urolithin A, the role of gut microbiota, metal ion transporter ZIP14, lysophosphatidylcholine and lysophosphatidylethanolamine, and BIO101, were described. It remains a fact, however, that effective treatments of cachexia and wasting disorders are urgently needed in order to improve patients' quality of life and their survival."],["dc.identifier.doi","10.1002/jcsm.12408"],["dc.identifier.pmid","30920774"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16328"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62269"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.relation.issn","2190-6009"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","10"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC neurology"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Scherbakov, Nadja"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Meisel, Andreas"],["dc.contributor.author","Haeusler, Karl Georg"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Anker, Stefan D"],["dc.contributor.author","Dirnagl, Ulrich"],["dc.contributor.author","Joebges, Michael"],["dc.contributor.author","Doehner, Wolfram"],["dc.date.accessioned","2019-07-09T11:42:18Z"],["dc.date.available","2019-07-09T11:42:18Z"],["dc.date.issued","2016"],["dc.description.abstract","BACKGROUND: Patients with stroke are at a high risk for long-term handicap and disability. In the first weeks after stroke muscle wasting is observed frequently. Early post-stroke rehabilitation programs are directed to improve functional independence and physical performance. Supplementation with essential amino acids (EAAs) might prevent muscle wasting and improve rehabilitation outcome by augmenting muscle mass and muscle strength. We aim to examine this in a double blinded, randomized placebo-controlled clinical trial. METHODS: Patients with ischemic or haemorrhagic stroke will be enrolled at begin of the early post-stroke rehabilitation in a parallel group interventional trial. Oral supplementation of EAAs or placebo will be given for 12 weeks in a double blinded manner. Physical and functional performance will be assessed by exercise testing before supplementation of EAAs as well as at discharge from the in-patient rehabilitation, at 12 weeks and 1 year afterwards. DISCUSSION: This is the first randomized double-blinded placebo-controlled clinical study aiming to assess the effect of the EAAs supplementation on muscle strength, muscle function and physical performance in stroke patients during early post-stroke rehabilitation. Supplementation of EAAs could prevent muscle mass wasting and improve functional independence after stroke. TRIAL REGISTRATION: The study is registered at the German registry for clinical trials as well as at World Health Organization (WHO; number DRKS00005577 )."],["dc.identifier.doi","10.1186/s12883-016-0531-5"],["dc.identifier.pmid","26793971"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13213"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58637"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1471-2377"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-Stroke Study)."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","611"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","620"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Scherbakov, Nadja"],["dc.contributor.author","Pietrock, Charlotte"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Springer, Jochen"],["dc.contributor.author","Schefold, Joerg C."],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Norman, Kristina"],["dc.contributor.author","Haeusler, Karl Georg"],["dc.date.accessioned","2021-06-01T10:50:54Z"],["dc.date.available","2021-06-01T10:50:54Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/jcsm.12400"],["dc.identifier.eissn","2190-6009"],["dc.identifier.issn","2190-5991"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16457"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86821"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Body weight changes and incidence of cachexia after stroke"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","508"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","511"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","von Haehling, Stephan"],["dc.date.accessioned","2018-11-07T10:22:57Z"],["dc.date.available","2018-11-07T10:22:57Z"],["dc.date.issued","2017"],["dc.description.abstract","This article highlights updates of pathways as well as pre-clinical and clinical studies into the field of wasting disorders that were presented at the 9th Cachexia Conference held in Berlin, Germany, December 2016. This year, some interesting results from clinical trials and different new therapeutic targets were shown. This article presents the biological and clinical significance of different markers and new diagnostic tools and cut-offs of detecting skeletal muscle wasting. Effective treatments of cachexia and wasting disorders are urgently needed in order to improve the patients' quality of life and their survival."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2017"],["dc.identifier.doi","10.1002/jcsm.12217"],["dc.identifier.isi","000403659900016"],["dc.identifier.pmid","28631415"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14541"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42367"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.relation.issn","2190-6009"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Highlights from the 9th Cachexia Conference"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1242"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","1249"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Garfias Macedo, Tania"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Bekfani, Tarek"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Schefold, Joerg C."],["dc.contributor.author","Lainscak, Mitja"],["dc.contributor.author","Cleland, John G. F."],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Anker, Stefan D."],["dc.date.accessioned","2021-04-14T08:24:54Z"],["dc.date.available","2021-04-14T08:24:54Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Background Skeletal muscle wasting is an extremely common feature in patients with heart failure, affecting approximately 20% of ambulatory patients with even higher values during acute decompensation. Its occurrence is associated with reduced exercise capacity, muscle strength, and quality of life. We sought to investigate if the presence of muscle wasting carries prognostic information. Methods Two hundred sixty‐eight ambulatory patients with heart failure (age 67.1 ± 10.9 years, New York Heart Association class 2.3 ± 0.6, left ventricular ejection fraction 39 ± 13.3%, and 21% female) were prospectively enrolled as part of the Studies Investigating Co‐morbidities Aggravating Heart Failure. Muscle wasting as assessed using dual‐energy X‐ray absorptiometry was present in 47 patients (17.5%). Results During a mean follow‐up of 67.2 ± 28.02 months, 95 patients (35.4%) died from any cause. After adjusting for age, New York Heart Association class, left ventricular ejection fraction, creatinine, N‐terminal pro‐B‐type natriuretic peptide, and iron deficiency, muscle wasting remained an independent predictor of death (hazard ratio 1.80, 95% confidence interval 1.01–3.19, P = 0.04). This effect was more pronounced in patients with heart failure with reduced than in heart failure with preserved ejection fraction. Conclusions Muscle wasting is an independent predictor of death in ambulatory patients with heart failure. Clinical trials are needed to identify treatment approaches to this co‐morbidity."],["dc.identifier.doi","10.1002/jcsm.12603"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17708"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81461"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Muscle wasting as an independent predictor of survival in patients with chronic heart failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","41"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","JCSM Rapid Communications"],["dc.bibliographiccitation.lastpage","43"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Ebner, Nicole"],["dc.date.accessioned","2020-09-16T11:21:00Z"],["dc.date.accessioned","2021-10-27T13:22:19Z"],["dc.date.available","2020-09-16T11:21:00Z"],["dc.date.available","2021-10-27T13:22:19Z"],["dc.date.issued","2020"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2020"],["dc.identifier.doi","10.1002/rco2.16"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92084"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","2617-1619"],["dc.relation.issn","2617-1619"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","JCSM Rapid Communications: from basic science to clinical research"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]